FDA's early review finds no evidence linking Novo, Lilly weight-loss drugs to suicidal thoughts

12 Jan 2024
www.fiercepharma.com
FDA's early review finds no evidence linking Novo, Lilly weight-loss drugs to suicidal thoughts
Preview
Source: FiercePharma
After reviewing data from clinical trials and observational studies, the FDA's preliminary review found no link to GLP-1 medicines and suicidal thoughts.
A preliminary evaluation by the FDA found no evidence that use of popular diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly can cause suicidal thoughts, the U.S. regulator said.
Over the last several months, the agency has been looking into reports of suicidal thoughts or actions from users of the GLP-1 treatments gathered through its FDA Adverse Event Reporting System (FAERS), it said.
“Because the information provided was often limited and because these events can be influenced by other potential factors, we determined that the information in these reports did not demonstrate a clear relationship with the use of (GLP-1s),” the FDA wrote. The agency said its reviews of clinical trials and observational studies found no association between the treatments and suicidal thoughts.
Ten days ago, the FDA drew attention when it included the trendy therapies on a list of medicines it said it was monitoring for side effects. In the case of Novo’s semaglutide and Lilly’s tirzepatide, those side effects also included alopecia (hair loss) and aspiration, a dangerous condition often associated with surgery in which people breathe food, liquid, vomit or saliva into their lungs.
In Thursday’s FDA update, the agency did not address those other potential side effects.
Also last week, Nature Journal reported that a study of 1.8 million patients in the United States found that those who were using Novo’s drugs such as Ozempic and Wegovy were less likely to have suicidal thoughts compared to patients who were using other diabetes and obesity treatments.
As demand has skyrocketed for the blood sugar-moderating drugs produced by Novo and Lilly, they have come under increased scrutiny. In July of last year, the European Medicines Agency began investigating Ozempic and Wegovy after reports from Iceland detailed suicidal thoughts from two users and self-harm from another. That review is ongoing.
GLP-1 drugs already include label warnings about a rare intestinal blockage condition called ileus, which can be life-threatening.
Through September of last year, the FDA had received 201 reports of suicidal thoughts from users of semaglutide or tirzepatide. In Thursday’s update, the FDA said that it would continue to monitor suicidal ideation in clinical trials and review data from the Sentinel System, a large network that includes health insurance claims and patient records that can be used to investigate safety questions about FDA-approved products.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.